WO2005116258A3 - Influenza hemagglutinin and neuraminidase varians - Google Patents

Influenza hemagglutinin and neuraminidase varians Download PDF

Info

Publication number
WO2005116258A3
WO2005116258A3 PCT/US2005/017729 US2005017729W WO2005116258A3 WO 2005116258 A3 WO2005116258 A3 WO 2005116258A3 US 2005017729 W US2005017729 W US 2005017729W WO 2005116258 A3 WO2005116258 A3 WO 2005116258A3
Authority
WO
WIPO (PCT)
Prior art keywords
neuraminidase
varians
influenza hemagglutinin
hemagglutinin
influenza
Prior art date
Application number
PCT/US2005/017729
Other languages
French (fr)
Other versions
WO2005116258A2 (en
Inventor
Chin-Fen Yang
George Kemble
Original Assignee
Medimmune Vaccines Inc
Chin-Fen Yang
George Kemble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Vaccines Inc, Chin-Fen Yang, George Kemble filed Critical Medimmune Vaccines Inc
Priority to CA2568015A priority Critical patent/CA2568015C/en
Priority to JP2007515199A priority patent/JP4980895B2/en
Priority to EP05780068A priority patent/EP1771552B1/en
Priority to ES05780068T priority patent/ES2394033T3/en
Priority to AU2005248375A priority patent/AU2005248375B2/en
Publication of WO2005116258A2 publication Critical patent/WO2005116258A2/en
Publication of WO2005116258A3 publication Critical patent/WO2005116258A3/en
Priority to AU2011201022A priority patent/AU2011201022B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Abstract

Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.
PCT/US2005/017729 2004-05-25 2005-05-20 Influenza hemagglutinin and neuraminidase varians WO2005116258A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2568015A CA2568015C (en) 2004-05-25 2005-05-20 Influenza hemagglutinin and neuraminidase variants
JP2007515199A JP4980895B2 (en) 2004-05-25 2005-05-20 Influenza hemagglutinin and neuraminidase variants
EP05780068A EP1771552B1 (en) 2004-05-25 2005-05-20 Influenza hemagglutinin and neuraminidase variants
ES05780068T ES2394033T3 (en) 2004-05-25 2005-05-20 Variants of hemagglutinin and influenza neuraminidase
AU2005248375A AU2005248375B2 (en) 2004-05-25 2005-05-20 Influenza hemagglutinin and neuraminidase varians
AU2011201022A AU2011201022B2 (en) 2004-05-25 2011-03-08 Influenza hemagglutinin and neuraminidase variants

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57455304P 2004-05-25 2004-05-25
US60/574,553 2004-05-25
US65755405P 2005-02-28 2005-02-28
US60/657,554 2005-02-28

Publications (2)

Publication Number Publication Date
WO2005116258A2 WO2005116258A2 (en) 2005-12-08
WO2005116258A3 true WO2005116258A3 (en) 2007-02-01

Family

ID=35451479

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/017733 WO2005116260A2 (en) 2004-05-25 2005-05-20 Influenza hemagglutinin and neuraminidase variants
PCT/US2005/017729 WO2005116258A2 (en) 2004-05-25 2005-05-20 Influenza hemagglutinin and neuraminidase varians

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2005/017733 WO2005116260A2 (en) 2004-05-25 2005-05-20 Influenza hemagglutinin and neuraminidase variants

Country Status (8)

Country Link
US (6) US7527800B2 (en)
EP (6) EP2902484A1 (en)
JP (2) JP4980895B2 (en)
AU (3) AU2005248377B2 (en)
CA (4) CA2879182C (en)
ES (5) ES2394033T3 (en)
HK (1) HK1179648A1 (en)
WO (2) WO2005116260A2 (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004272972A1 (en) 2003-05-22 2005-03-24 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
EP2581093B1 (en) 2003-06-16 2015-03-18 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
US9254315B2 (en) * 2004-04-28 2016-02-09 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
AU2011202991B2 (en) * 2004-05-25 2012-12-20 Medlmmune, Llc Influenza hemagglutinin and neuraminidase variants
WO2005116260A2 (en) * 2004-05-25 2005-12-08 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
JP4786548B2 (en) 2004-11-01 2011-10-05 栄研化学株式会社 Method for detecting H5 avian influenza virus
BRPI0518728A2 (en) * 2004-12-09 2008-12-02 Univ Pittsburgh vaccines for rapid response to avian influenza pandemic
EP2471552B1 (en) 2005-03-08 2015-05-06 MedImmune, LLC Reassortant influenza viruses
EP1919504B1 (en) * 2005-08-03 2013-10-16 iBio, Inc. Antibody to bacillus anthracis protective antigen
BRPI0618254A2 (en) * 2005-11-04 2011-08-23 Novartis Vaccines & Diagnostic free aqueous phase surfactant emulsions to provide adjuvant to split influenza vaccines
CA2631812C (en) 2005-12-02 2023-08-29 Peter Palese Chimeric viruses presenting non-native surface proteins and uses thereof
WO2008048344A2 (en) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
CA2642056A1 (en) * 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Hpv antigens, vaccine compositions, and related methods
SG10201806098QA (en) 2006-02-13 2018-08-30 Us Gov Health & Human Services Primers and probes for detection and discrimination of types and subtypes of influenza viruses
EP1984405A4 (en) * 2006-02-13 2010-06-30 Fraunhofer Usa Inc Influenza antigens, vaccine compositions, and related methods
RU2318871C1 (en) * 2006-04-19 2008-03-10 ГУ "Научно-исследовательский институт экспериментальной медицины" РАМН /ГУ НИИЭМ РАМН/ Strain of influenza virus gkv 2389 for production of living intranasal and inactivated influenza vaccine
BRPI0713671A2 (en) 2006-06-16 2013-12-03 Dow Agrosciences Llc DNA SEQUENCES, VECTORS AND PROTEINS OF HEMAGLUTININ FROM AVIAN INFLUENZA
US20080003203A1 (en) * 2006-06-28 2008-01-03 National Tsing Hua University Pseudotyped baculovirus to stimulate immunogenicity against avian influenza
AU2013206611B2 (en) * 2006-08-09 2016-01-14 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
KR101559184B1 (en) * 2006-08-09 2015-10-13 메디뮨 엘엘씨 Influenza hemagglutinin and neuraminidase variants
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
US8778348B2 (en) * 2007-04-28 2014-07-15 Ibio Inc. Trypanosoma antigens, vaccine compositions, and related methods
US8778847B2 (en) 2007-06-13 2014-07-15 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides of influenza virus
KR101466326B1 (en) * 2007-06-15 2014-12-02 주식회사 바이오트라이온 An attenuated influenza virus and a live vaccine comprising the same
EP2178558B1 (en) 2007-07-11 2014-04-30 iBio, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
US8084594B2 (en) * 2007-07-13 2011-12-27 The United States Of America As Represented By The Secretary Of Agriculture H2N3 influenza A viruses and methods of use
US20110059130A1 (en) * 2007-08-20 2011-03-10 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions and methods
US8470771B2 (en) * 2007-11-14 2013-06-25 Institute Of Microbiology, Chinese Academy Of Sciences Method and medicament for inhibiting the infection of influenza virus
RU2523587C2 (en) * 2008-07-11 2014-07-20 МЕДИММЬЮН, ЭлЭлСи Versions of hemagglutinin and neuraminidase of influenza virus
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
US9884105B2 (en) 2008-12-16 2018-02-06 Ology Bioservices, Inc. Production of viral vaccine
CA2751379C (en) 2009-02-10 2018-06-12 Novartis Ag Influenza vaccines with reduced amounts of squalene
WO2010093537A2 (en) * 2009-02-12 2010-08-19 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
JP2012521786A (en) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ Influenza virus vaccine and use thereof
CA2757030C (en) * 2009-04-03 2019-01-15 Merial Limited Vectors comprising newcastle disease viruses and compositions thereof
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
EP2258398A1 (en) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
US9849173B2 (en) 2009-07-06 2017-12-26 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011041391A1 (en) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
CA2785867C (en) * 2009-12-28 2018-03-27 Dsm Ip Assets B.V. Production of hemagglutinin-neuraminidase protein in microalgae
CA2785971C (en) * 2009-12-28 2019-02-12 Dsm Ip Assets B.V. Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
US20110184160A1 (en) * 2010-01-26 2011-07-28 Weiner David B Nucleic acid molecule encoding consensus influenza a hemagglutinin h1
JP2013520172A (en) * 2010-02-18 2013-06-06 モウント シナイ スクール オフ メディシネ Vaccines for use in the prevention and treatment of influenza virus diseases
EP3900740A1 (en) 2010-03-30 2021-10-27 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
US9610248B2 (en) 2010-07-06 2017-04-04 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
US8513006B2 (en) 2010-09-14 2013-08-20 University of Pittsburgh—of the Commonwealth System of Higher Education Tetravalent influenza vaccine and use thereof
BR112013007946B1 (en) * 2010-10-04 2022-07-12 Massachusetts Institute Of Technology PHARMACEUTICAL AND IMMUNOGENIC COMPOSITIONS COMPRISING HEMAGGLUTININ POLYPEPTIDES
WO2012061239A2 (en) * 2010-11-02 2012-05-10 Opko Pharmaceuticals, Llc Novel vaccines against pandemic influenza virus a/h1n1
KR20130140050A (en) * 2010-11-02 2013-12-23 헥토 마뉴엘 제페다 로페즈 Novel vaccines against the a/h1n1 pandemic flu virus
CN103501811B (en) 2011-01-13 2016-03-30 变异生物技术公司 Be used for the treatment of compositions and the method for viral infection
MX357319B (en) 2011-01-13 2018-07-04 Variation Biotechnologies Inc Methods for preparing vesicles and formulations produced therefrom.
AR088028A1 (en) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed PROTEINS H5, FROM H5N1 FOR MEDICINAL USE
CN102304495A (en) * 2011-09-08 2012-01-04 中国农业科学院上海兽医研究所 Recombinant influenza virus capable of expressing HA (hemagglutinin) protein with high efficiency and preparation method and application thereof
CN104185476A (en) 2011-09-20 2014-12-03 西奈山医学院 Influenza virus vaccines and uses thereof
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
AU2013213345A1 (en) 2012-01-27 2014-08-28 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
KR101481986B1 (en) * 2012-07-23 2015-01-19 연세대학교 산학협력단 Live vaccine protecting against pathogenic avian influenza H5N1 and use thereof
SG11201504728RA (en) 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
WO2014127825A1 (en) * 2013-02-21 2014-08-28 Boehringer Ingelheim Vetmedica Gmbh H5 proteins of h5n1 influenza virus for use as a medicament
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
CA2906823C (en) 2013-03-15 2023-01-03 The Research Foundation For The State University Of New York Attenuated influenza viruses and vaccines
EP3060686B1 (en) 2013-10-22 2018-08-01 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Compositions and methods for detection of influenza viruses
EP3247389A4 (en) 2015-01-23 2019-10-30 Icahn School of Medicine at Mount Sinai Influenza virus vaccination regimens
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN109641041A (en) 2016-06-15 2019-04-16 西奈山伊坎医学院 Influenza virus haemagglutinin albumen and application thereof
CN106939355A (en) * 2017-03-01 2017-07-11 苏州系统医学研究所 A kind of screening of influenza virus attenuated live vaccines strain and authentication method
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
US20210046176A1 (en) * 2018-03-28 2021-02-18 Sanofi Pasteur Inc. Methods of generating broadly protective vaccine compositions comprising neuraminidase
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
AU2020248404A1 (en) 2019-03-25 2021-09-30 Visterra, Inc. Compositions and methods for treating and preventing influenza
US20230285536A1 (en) * 2020-06-24 2023-09-14 Trustees Of Tufts College Edible cell based vaccines
CN113150083B (en) * 2021-04-29 2023-03-24 山西高等创新研究院 Recombinant avian influenza subunit vaccine and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119445A1 (en) * 1996-02-23 2002-08-29 Parkin Neil T. Novel recombinant tryptophan mutants of influenza

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US3992522A (en) 1973-01-24 1976-11-16 The United States Of America As Represented By The Department Of Health, Education And Welfare Temperature-sensitive recombinant mutant viruses and a process for producing same
US4071618A (en) * 1974-09-03 1978-01-31 Research Foundation For Microbial Diseases Of Osaka University Process for preparing virus disease live vaccines
JPS57136528A (en) 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
CH652145A5 (en) 1982-01-22 1985-10-31 Sandoz Ag METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4752473A (en) * 1984-10-12 1988-06-21 The Regents Of The University Of California Expression of glycosylated human influenza hemagglutinin proteins
US4656569A (en) * 1985-10-22 1987-04-07 Hugh Buskell Elevating apparatus particularly for the canopy of a lamp standard
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US6001634A (en) * 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5840520A (en) * 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5854037A (en) * 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5665362A (en) * 1990-09-25 1997-09-09 Cantab Pharmaceuticals Research Limited Viral vaccines
ES2247584T3 (en) 1992-04-14 2006-03-01 The Mount Sinai School Of Medicine Of The City University Of New York VIRUSES ATTENED BY GENETIC ENGINEERING.
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Attenuated respiratory syncytial virus vaccine compositions
CA2110242C (en) * 1992-11-27 2001-01-23 Masayoshi Aihara Portable facsimile equipment
DE4301103C1 (en) * 1993-01-18 1994-08-18 Voith Gmbh J M Screen section of a paper machine
US7094597B1 (en) * 1994-05-20 2006-08-22 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
PT702085E (en) * 1994-07-18 2004-04-30 Karl Klaus Conzelmann NON-SEGMENTED CHEMICAL RNA VIRUS INFECTIOUS RECOMBINANT
US5716821A (en) 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
WO1996010400A1 (en) 1994-09-30 1996-04-11 The Uab Research Foundation Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US5756341A (en) * 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5690937A (en) 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene
DE69510207T3 (en) 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Process for producing infectious minus-stranded RNA viruses
WO1997012032A1 (en) 1995-09-27 1997-04-03 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of infectious respiratory syncytial virus from cloned nucleotide sequences
DE69634904T2 (en) 1995-10-31 2006-05-18 Dnavec Research Inc., Tsukuba NEGATIVE STONE RNA VIRUS WITH SELF-ACTIVE REPLICATION ACTIVITY
ATE470704T1 (en) 1995-11-01 2010-06-15 Dnavec Research Inc RECOMBINANT SENDAI VIRUS
AU3799797A (en) 1996-07-15 1998-02-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
BR9712138A (en) 1996-09-27 2000-01-18 American Cyanamid Co Isolated RNA virus, vaccine, process to immunize an individual to induce protection against a non-segmented, negative, single-stranded RNA virus of the mononegaviral order and to produce RNA virus, isolated nucleic acid molecule and composition.
DE69842165D1 (en) 1997-05-23 2011-04-21 Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services PREPARATION OF ATTENUATED PARAIN FLUENZA VIRUS VACCINES FROM CLONED NUCLEOTIDE SEQUENCES
ATE361973T1 (en) 1997-07-11 2007-06-15 Univ Yale RHABDOVIRUS WITH A GENETICALLY MODIFIED CASE
EP1015594A1 (en) 1997-09-19 2000-07-05 American Cyanamid Company Attenuated respiratory syncytial viruses
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
EP1035209A1 (en) 1999-03-06 2000-09-13 ARTEMIS Pharmaceuticals GmbH Stable recombinant influenza viruses free of helper viruses
CA2365526C (en) 1999-04-06 2016-07-05 Wisconsin Alumni Research Foundation Recombinant influenza viruses for vaccines and gene therapy
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
AU5035201A (en) 2000-03-02 2001-09-12 Polymun Scient Immunbio Forsch Recombinant influenza a viruses
NZ521840A (en) 2000-04-28 2004-11-26 St Development of a multi-plasmid pol I - pol II based system for the generation of infectious influenza RNA viruses from cloned DNA
JP5063852B2 (en) 2000-09-25 2012-10-31 ポリマン サイエンティフィック イミューンバイオロジッシュ フォーシュング ゲゼルシャフト ミット ベシュレンクテル ファフツング Live vaccine and production method
USPP15035P3 (en) * 2001-06-27 2004-07-27 Marko Zaninovich, Inc. Grapevine ‘12-76-71’
KR100600988B1 (en) 2002-03-13 2006-07-13 주식회사 엘지생명과학 Method for enhancing immune responses by codelivering influenza NP DNA in DNA immunization
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
CN103540568A (en) 2002-04-26 2014-01-29 米迪缪尼有限公司 Multi plasmid system for the production of influenza virus
EP2581093B1 (en) 2003-06-16 2015-03-18 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
US20080057071A1 (en) * 2003-10-20 2008-03-06 Watkins David N Use Of Hedgehog Pathway Inhibitors In Small-Cell Lung Cancer
WO2005116260A2 (en) * 2004-05-25 2005-12-08 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
JP4786548B2 (en) 2004-11-01 2011-10-05 栄研化学株式会社 Method for detecting H5 avian influenza virus
EP2471552B1 (en) * 2005-03-08 2015-05-06 MedImmune, LLC Reassortant influenza viruses
KR101559184B1 (en) * 2006-08-09 2015-10-13 메디뮨 엘엘씨 Influenza hemagglutinin and neuraminidase variants
US8084594B2 (en) * 2007-07-13 2011-12-27 The United States Of America As Represented By The Secretary Of Agriculture H2N3 influenza A viruses and methods of use
WO2010093537A2 (en) 2009-02-12 2010-08-19 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119445A1 (en) * 1996-02-23 2002-08-29 Parkin Neil T. Novel recombinant tryptophan mutants of influenza

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
See also references of EP1771552A4 *
SUBBARAO K. ET AL.: "Evaluation of a Genetically Modified Reassortant H5N1 Influenza A Virus Vaccine Candidate Generated by Plasmid-Based Reverse Genetics", VIROLOGY, vol. 305, 2003, pages 192 - 200, XP002331121 *
WAREING ET AL.: "Immunogenic and Isotype-Specific Responses to Russian and US Cold-Adapted Influenza A Vaccine Donor Strains A/Leningrad/134/17/57, A/Leningrad/134/47/57, and A/Ann Arbor/6/60 (H2N2) in Mice", JOURNAL MED. VIROL., vol. 65, December 2001 (2001-12-01), pages 171 - 177, XP008078476 *
WEBBY R. ET AL.: "Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines", THE LANCET, vol. 363, 3 April 2004 (2004-04-03), pages 1099 - 1103, XP004852899 *

Also Published As

Publication number Publication date
ES2393492T3 (en) 2012-12-21
AU2005248375A1 (en) 2005-12-08
CA2568020C (en) 2015-04-07
JP4980895B2 (en) 2012-07-18
ES2525672T3 (en) 2014-12-29
EP2465927B1 (en) 2014-12-24
US7504109B2 (en) 2009-03-17
WO2005116260A2 (en) 2005-12-08
HK1179648A1 (en) 2013-10-04
JP2008500041A (en) 2008-01-10
US20110052618A1 (en) 2011-03-03
EP1766059A4 (en) 2010-03-31
ES2454266T3 (en) 2014-04-10
US20120034264A1 (en) 2012-02-09
CA2822895A1 (en) 2005-12-08
EP2522719A1 (en) 2012-11-14
ES2533382T3 (en) 2015-04-09
AU2011201022B2 (en) 2012-04-26
AU2005248377B2 (en) 2011-03-24
US8765136B2 (en) 2014-07-01
CA2568015A1 (en) 2005-12-08
ES2394033T3 (en) 2013-01-15
EP1771552A4 (en) 2009-10-21
EP1766059B1 (en) 2012-07-11
EP2522719B1 (en) 2013-12-25
EP2465927A1 (en) 2012-06-20
EP1771552A2 (en) 2007-04-11
WO2005116258A2 (en) 2005-12-08
CA2568015C (en) 2013-08-27
EP2530147B1 (en) 2014-09-10
JP4980896B2 (en) 2012-07-18
JP2008500042A (en) 2008-01-10
AU2011201022A1 (en) 2011-03-31
AU2005248375B2 (en) 2010-12-16
US7744901B2 (en) 2010-06-29
EP2902484A1 (en) 2015-08-05
US20050287172A1 (en) 2005-12-29
AU2005248377A1 (en) 2005-12-08
US20090175909A1 (en) 2009-07-09
EP1771552B1 (en) 2012-08-01
CA2879182C (en) 2017-02-14
CA2568020A1 (en) 2005-12-08
US20060008473A1 (en) 2006-01-12
EP1766059A2 (en) 2007-03-28
WO2005116260A3 (en) 2009-02-26
EP2530147A2 (en) 2012-12-05
CA2879182A1 (en) 2005-12-08
US7527800B2 (en) 2009-05-05
US20090136530A1 (en) 2009-05-28
US7981429B2 (en) 2011-07-19
EP2530147A3 (en) 2013-02-27

Similar Documents

Publication Publication Date Title
WO2005116258A3 (en) Influenza hemagglutinin and neuraminidase varians
WO2008021959A3 (en) Influenza hemagglutinin and neuraminidase variants
WO2006098901A3 (en) Influenza hemagglutinin and neuraminidase variants
WO2010006144A3 (en) Influenza hemagglutinin and neuraminidase variants
WO2005018539A8 (en) Influenza hemagglutinin and neuraminidase variants
EP1819357A4 (en) Vaccines for the rapid response to pandemic avian influenza
WO2008112017A3 (en) Avian influenza vaccine
AP2008004625A0 (en) Avian influenza viruses, vaccines, compositions, formulations, and methods
HUE049580T2 (en) Influenza vaccines containing hemagglutinin and matrix proteins
ZA200808845B (en) Novel DNA sequences, vectors and proteins of Avian Influenza hemagglutinin
EP1603590A4 (en) Influenza virus vaccine
MX2012000123A (en) Swine influenza hemagglutinin variants.
EP1906998A4 (en) Peptide-based influenza vaccine formulation
DK3326673T3 (en) SPRAYERS, SPRAY INTERFACES AND SPRAY STAMPS FOR USE WITH MEDICAL INJECTORS
HK1134781A1 (en) Feline vaccines against avian influenza
EP3810634A4 (en) Mosaic influenza virus hemagglutinin polypeptides and uses thereof
EP1761645A4 (en) Diagnostic primers and method for detecting avian influenza virus subtype h5 and h5n1
IL186710A (en) Isolated canine influenza a virus, compositions and vaccine comprising it and use of same
AP2167A (en) Multivalent avian influenza vaccines.
ZA200905952B (en) Lyophilized preparation comprising influenza vaccine,and method for preparation thereof
MX343411B (en) Influenza hemagglutinin and neuraminidase variants.
WO2007076091A3 (en) Treatment of viral infections using a tissue factor inhibitor
DK1906921T3 (en) Clear pharmaceutical aqueous microemulsion comprising propofol and method of preparation
BRPI0719170A2 (en) method for the treatment of sub-fertility, use of a vitamin d compound, pharmaceutical formulation, vitamin d compound, and kit.
Yu Terms about Influenza A (H1N1)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2568015

Country of ref document: CA

Ref document number: 2007515199

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005248375

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005780068

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005248375

Country of ref document: AU

Date of ref document: 20050520

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005248375

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005780068

Country of ref document: EP